Evoke Pharma, Inc. (EVOK) DCF Valuation

Evoke Pharma, Inc. (EVOK) Valoración de DCF

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
Evoke Pharma, Inc. (EVOK) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Evoke Pharma, Inc. (EVOK) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Simplifique la valoración de Evoke Pharma, Inc. (EVOK) con esta calculadora DCF personalizable! Con Real Evoke Pharma, Inc. (EVOK) financieras y entradas de pronóstico ajustables, puede probar escenarios y descubrir EVOKE Pharma, Inc. (EVOK) Valor razonable en minutos.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 1.6 2.5 5.2 8.5 13.9 22.8 37.3 61.0
Revenue Growth, % 0 0 6929 55.04 106.51 63.76 63.76 63.76 63.76 63.76
EBITDA .0 -13.0 -8.0 -7.7 -7.3 -5.1 -8.3 -13.7 -22.4 -36.6
EBITDA, % 100 -56653.68 -496.76 -307.9 -140.76 -60 -60 -60 -60 -60
Depreciation 7.2 13.0 8.2 7.8 .1 6.8 11.2 18.3 30.0 49.1
Depreciation, % 100 56678.32 503.79 310.37 2.68 80.54 80.54 80.54 80.54 80.54
EBIT -7.2 -26.1 -16.2 -15.5 -7.4 -5.1 -8.3 -13.7 -22.4 -36.6
EBIT, % 100 -113332 -1000.54 -618.27 -143.44 -60 -60 -60 -60 -60
Total Cash 5.7 8.1 9.1 9.8 4.7 8.3 13.7 22.4 36.6 60.0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .3 .6 .7
Account Receivables, % 100 101.26 18.24 24.91 12.99
Inventories .0 .2 .2 .3 .5 3.9 6.5 10.6 17.3 28.3
Inventories, % 100 1027.28 11.47 11.54 9.3 46.46 46.46 46.46 46.46 46.46
Accounts Payable 1.0 1.3 .9 .9 1.7 5.5 8.9 14.6 24.0 39.3
Accounts Payable, % 100 5532.46 54.02 34.61 33.04 64.33 64.33 64.33 64.33 64.33
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 0 0 0 -0.000057908015 -0.000011581603 -0.000011581603 -0.000011581603 -0.000011581603 -0.000011581603
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -7.1 -26.3 -17.1 -15.4 -7.4 -5.1 -8.3 -13.6 -22.3 -36.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 1.1 -13.3 -9.6 -8.0 -6.7 -1.6 1.1 1.7 2.9 4.7
WACC, % 9.14 9.17 9.17 9.11 9.17 9.15 9.15 9.15 9.15 9.15
PV UFCF
SUM PV UFCF 5.8
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 5
Terminal Value 67
Present Terminal Value 43
Enterprise Value 49
Net Debt 0
Equity Value 49
Diluted Shares Outstanding, MM 0
Equity Value Per Share 174.90

What You Will Get

  • Real Evoke Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Evoke Pharma, Inc. (EVOK).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Evoke Pharma.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Evoke Pharma’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Evoke Pharma, Inc. (EVOK).
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility tailored to Evoke Pharma.

Key Features

  • Accurate Financial Data: Gain access to reliable pre-loaded historical data and future forecasts for Evoke Pharma, Inc. (EVOK).
  • Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
  • Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
  • User-Friendly Dashboard: Intuitive charts and summaries to help you visualize your valuation outcomes.
  • Designed for All Skill Levels: A straightforward, user-friendly layout tailored for investors, CFOs, and consultants alike.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Evoke Pharma's (EVOK) data.
  • Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view the recalculated results, including Evoke Pharma's intrinsic value.
  • Step 5: Make informed investment decisions or create reports based on the outputs.

Why Choose the Evoke Pharma Calculator?

  • All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for Evoke Pharma (EVOK).
  • Flexible Parameters: Modify the highlighted cells to explore different financial scenarios.
  • In-Depth Analysis: Automatically computes Evoke Pharma’s intrinsic value and Net Present Value.
  • Preloaded Information: Historical and projected data provide reliable foundations for analysis.
  • Expert-Level Design: Perfect for financial analysts, investors, and business advisors focusing on Evoke Pharma (EVOK).

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Evoke Pharma, Inc. (EVOK) stock.
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models for Evoke Pharma, Inc. (EVOK).
  • Consultants: Deliver professional valuation insights on Evoke Pharma, Inc. (EVOK) to clients quickly and accurately.
  • Business Owners: Understand how biotech companies like Evoke Pharma, Inc. (EVOK) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to Evoke Pharma, Inc. (EVOK).

What the Template Contains

  • Pre-Filled Data: Includes Evoke Pharma’s historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Evoke Pharma’s profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

No products were found matching.